| Status: Assessment pending - company submission requested | |
For the emergency treatment of allergic reactions (anaphylaxis), and idiopathic or exercise induced anaphylaxis, in adults and children weighing 30kg or more |
|
Medicine details |
|
| Medicine name | Intranasal adrenaline (EURneffy) |
| Formulation | 2 mg in 100 microlitres nasal spray, solution in single-dose container |
| Reference number | 6284 |
| Indication | As above |
| Company | ALK Abello |
| BNF chapter | Respiratory system |
| Assessment type | Limited |
| Status | Assessment pending - company submission requested |
| Scrutiny Panel meeting date | 05/03/2026 |
| Further information This medicine was considered by AWMSG Scrutiny Panel on 3 March 2026. Intranasal adrenaline (EURneffy®) is suitable for a limited assessment via the Licensed Medicines One Wales Medicines Assessment Group (LOWMAG). The anticipated budget impact is considered to be low and the product may be cost saving in comparison to adrenaline autoinjectors due to having a potentially longer average shelf life. Clinical equivalence of adrenaline delivered intranasally versus by autoinjector is sufficiently established for the MHRA to license and for the British Society of Clinically Allergy and Immunology to consider it a suitable alternative for the majority of patients. A limited submission has been requested from the company. |
|